145 related articles for article (PubMed ID: 3532603)
1. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen.
Alving CR; Richards RL; Moss J; Alving LI; Clements JD; Shiba T; Kotani S; Wirtz RA; Hockmeyer WT
Vaccine; 1986 Sep; 4(3):166-72. PubMed ID: 3532603
[TBL] [Abstract][Full Text] [Related]
2. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine.
Alving CR; Richards RL
Immunol Lett; 1990 Aug; 25(1-3):275-9. PubMed ID: 2283158
[TBL] [Abstract][Full Text] [Related]
3. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen.
Richards RL; Hayre MD; Hockmeyer WT; Alving CR
Infect Immun; 1988 Mar; 56(3):682-6. PubMed ID: 3277918
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.
Richards RL; Swartz GM; Schultz C; Hayre MD; Ward GS; Ballou WR; Chulay JD; Hockmeyer WT; Berman SL; Alving CR
Vaccine; 1989 Dec; 7(6):506-12. PubMed ID: 2692333
[TBL] [Abstract][Full Text] [Related]
5. Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.
Que JU; Cryz SJ; Ballou R; Fürer E; Gross M; Young J; Wasserman GF; Loomis LA; Sadoff JC
Infect Immun; 1988 Oct; 56(10):2645-9. PubMed ID: 3047062
[TBL] [Abstract][Full Text] [Related]
6. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.
Lowell GH; Ballou WR; Smith LF; Wirtz RA; Zollinger WD; Hockmeyer WT
Science; 1988 May; 240(4853):800-2. PubMed ID: 2452484
[TBL] [Abstract][Full Text] [Related]
7. Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.
Hui GS; Tam LQ; Chang SP; Case SE; Hashiro C; Siddiqui WA; Shiba T; Kusumoto S; Kotani S
Infect Immun; 1991 May; 59(5):1585-91. PubMed ID: 2019429
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum.
Ballou WR; Rothbard J; Wirtz RA; Gordon DM; Williams JS; Gore RW; Schneider I; Hollingdale MR; Beaudoin RL; Maloy WL
Science; 1985 May; 228(4702):996-9. PubMed ID: 2988126
[TBL] [Abstract][Full Text] [Related]
9. Liposomes as vehicles for vaccines.
Alving CR; Banerji B; Shiba T; Kotani S; Clements JD; Richards RL
Prog Clin Biol Res; 1980; 47():339-55. PubMed ID: 7208512
[TBL] [Abstract][Full Text] [Related]
10. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines.
Hui GS
Am J Trop Med Hyg; 1994; 50(4 Suppl):41-51. PubMed ID: 8172331
[TBL] [Abstract][Full Text] [Related]
11. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.
Richards RL; Rao M; Wassef NM; Glenn GM; Rothwell SW; Alving CR
Infect Immun; 1998 Jun; 66(6):2859-65. PubMed ID: 9596760
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45.
Pritsch M; Ben-Khaled N; Chaloupka M; Kobold S; Berens-Riha N; Peter A; Liegl G; Schubert S; Hoelscher M; Löscher T; Wieser A
J Immunol Res; 2016; 2016():3576028. PubMed ID: 27239480
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and efficacy trials in Aotus nancymai monkeys with model compounds representing parts of a 75-kD merozoite surface antigen of Plasmodium falciparum.
Sharma P; Ruebush TK; Campbell GH; Richman SJ; Wilkins PP; Broderson JR; Ardeshir F; Gross M; Silverman C; Skinner JC
Am J Trop Med Hyg; 1992 Jun; 46(6):691-707. PubMed ID: 1621894
[TBL] [Abstract][Full Text] [Related]
14. Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.
Lowell GH; Ballou WR; Smith LF; Zollinger WD; Hockmeyer WT
Trans R Soc Trop Med Hyg; 1989; 83 Suppl():101-2. PubMed ID: 2696152
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antibody responses to the circumsporozoite protein repeat region and to intact sporozoites during acute falciparum malaria.
Brown AE; Webster HK; Pavanand K; Permpanich B; Sookto P; Sattabongkot J; Gingrich JB
Trans R Soc Trop Med Hyg; 1989; 83(2):154-7. PubMed ID: 2692219
[TBL] [Abstract][Full Text] [Related]
16. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine.
Young JF; Hockmeyer WT; Gross M; Ballou WR; Wirtz RA; Trosper JH; Beaudoin RL; Hollingdale MR; Miller LH; Diggs CL
Science; 1985 May; 228(4702):958-62. PubMed ID: 2988125
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.
Ballou WR; Hoffman SL; Sherwood JA; Hollingdale MR; Neva FA; Hockmeyer WT; Gordon DM; Schneider I; Wirtz RA; Young JF
Lancet; 1987 Jun; 1(8545):1277-81. PubMed ID: 2884410
[TBL] [Abstract][Full Text] [Related]
18. A multiple antigen peptide from the repetitive sequence of the Plasmodium malariae circumsporozoite protein induces a specific antibody response in mice of various H-2 haplotypes.
Del Giudice G; Tougne C; Louis JA; Lambert PH; Bianchi E; Bonelli F; Chiappinelli L; Pessi A
Eur J Immunol; 1990 Jul; 20(7):1619-22. PubMed ID: 2201549
[TBL] [Abstract][Full Text] [Related]
19. Malaria vaccine against sporozoites?
Nussenzweig V; Nussenzweig RS
Ann Inst Pasteur Immunol (1985); 1985; 136D(3):301-12. PubMed ID: 3913382
[TBL] [Abstract][Full Text] [Related]
20. [Malaria vaccine research].
Sellioğlu B
Mikrobiyol Bul; 1986 Jan; 20(1):37-41. PubMed ID: 3523172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
